Barclays backs biotech with fresh calls on oncology and immunology stocks

Barclays initiated coverage on a selection of small- and mid-cap biotechnology companies, predominantly in oncology and immunology, projecting "meaningful opportunities for stock upside through year-end 2026" despite increasing competition. The firm issued Overweight ratings for several firms, including C4 Therapeutics (193% upside potential) and Janux Therapeutics (87% upside), citing promising clinical data and utilizing a sum-of-the-parts discounted cash flow model with phase-specific probabilities of success. Conversely, Summit Therapeutics and Xencor received Underweight ratings, underscoring Barclays' selective approach and the critical importance of stock picking in a sector where indices are noted to underperform broader markets.

Analysis

Barclays has initiated coverage on a portfolio of small- and mid-cap biotechnology firms, primarily focused on oncology and immunology, signaling a positive long-term outlook for innovation within these sectors. The firm underscores that positive clinical data is the principal driver of stock outperformance and stresses the necessity of selective stock-picking, as biotech indices tend to underperform broader markets. Highlighting this selectivity, Barclays issued several "Overweight" ratings with significant upside potential, including C4 Therapeutics (CCCC) with a 193% upside to an $8 target based on promising early data for cemsidomide, and Terns Pharmaceuticals (TERN) with a 102% upside to a $15 target ahead of expected Q4 data for its leukemia candidate. Other notable "Overweight" ratings backed by specific catalysts include Janux Therapeutics (JANX, 87% upside) for its prostate cancer data, and Merus N.V. (MRUS, 60% upside) for its antibody platform. In contrast, Summit Therapeutics (SMMT) was initiated at "Underweight" with a projected 30% downside, as Barclays sees insufficient differentiation in its lung cancer asset. Xencor (XNCR) also received an "Underweight" rating. The analysis is underpinned by a sum-of-the-parts discounted cash flow model, which systematically applies success probabilities of 15%, 35%, and 65% to assets in Phase 1, 2, and 3, respectively, providing a structured framework for valuing these high-risk, high-reward opportunities.

Key Decisions for Investors

• Investors with a high-risk tolerance should evaluate the "Overweight" rated companies, particularly C4 Therapeutics (CCCC) and Terns Pharmaceuticals (TERN), which Barclays identifies as having over 100% upside potential contingent on near-term clinical data catalysts.
• Caution is advised for positions in Summit Therapeutics (SMMT) and Xencor (XNCR), as the "Underweight" ratings signal a perceived lack of competitive differentiation and potential for significant downside relative to peers.
• Monitor companies with upcoming clinical milestones, such as Terns Pharmaceuticals' expected Q4 data readout, as these events represent key inflection points that Barclays identifies as the primary driver of stock performance in the sector.
• For long-term positions, consider companies with extended cash runways like Merus (MRUS) and Protagonist Therapeutics (PTGX), both funded through at least 2028, as this financial stability mitigates near-term financing risks common in the biotech industry.